UMIN-CTR Clinical Trial

Unique ID issued by UMIN UMIN000042253
Receipt number R000048236
Scientific Title Impact of androgen deprivation therapy on cognitive function in patients with prostate cancer.
Date of disclosure of the study information 2020/10/27
Last modified on 2022/11/08 11:30:27

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information

Public title

Impact of androgen deprivation therapy on cognitive function in patients with prostate cancer.

Acronym

Impact of androgen deprivation therapy on cognitive function in patients with prostate cancer.

Scientific Title

Impact of androgen deprivation therapy on cognitive function in patients with prostate cancer.

Scientific Title:Acronym

Impact of androgen deprivation therapy on cognitive function in patients with prostate cancer.

Region

Japan


Condition

Condition

Prostate cancer

Classification by specialty

Urology

Classification by malignancy

Malignancy

Genomic information

NO


Objectives

Narrative objectives1

Androgen deprivation therapy (ADT) is effective as a systemic therapy for metastatic prostate cancer or as an in conjunction with radiotherapy for localized disease.
The use of ADT has also been associated with various adverse events as a consequence of testosterone deficiency. Recently, several studies have also examined the impact of ADT on cognitive function. However, these findings are still controversial.
In this study, we prospectively investigated the relationship between ADT and cognitive impairment in patients with PCa.

Basic objectives2

Others

Basic objectives -Others

Primary endopoint: Comparison of the change in cognitive function between patients with prostate cancer treated with androgen deprivation therapy and control group.
Secondary endopoint: Relationship between the change in cognitive function and patients' characteristics.

Trial characteristics_1

Exploratory

Trial characteristics_2


Developmental phase

Not applicable


Assessment

Primary outcomes

Comparison of the change in cognitive function between patients with prostate cancer treated with androgen deprivation therapy and control group.

Key secondary outcomes

Relationship between the change in cognitive function and patients' characteristics.


Base

Study type

Observational


Study design

Basic design


Randomization


Randomization unit


Blinding


Control


Stratification


Dynamic allocation


Institution consideration


Blocking


Concealment



Intervention

No. of arms


Purpose of intervention


Type of intervention


Interventions/Control_1


Interventions/Control_2


Interventions/Control_3


Interventions/Control_4


Interventions/Control_5


Interventions/Control_6


Interventions/Control_7


Interventions/Control_8


Interventions/Control_9


Interventions/Control_10



Eligibility

Age-lower limit

20 years-old <=

Age-upper limit


Not applicable

Gender

Male

Key inclusion criteria

Prostate cancer group
1.Patients who received androgen deprivation therapy.
2.Eastern Cooperative Oncology Group performance status (ECOG-PS): 0-2.
3.Expected survival is more than 12 months.
4.Patients who understand this research plan and have given their consent.

Control group
1.Patients with suspected prostate cancer who require regular monitoring.
2.Eastern Cooperative Oncology Group performance status (ECOG-PS): 0-2.
3.Expected survival is more than 12 months.
4.Patients who understand this research plan and have given their consent.

Key exclusion criteria

1.Patients with active other malignancy.
2.Patients with or confirmed a history of cognitive impairment.
3.Patients with other serious disease or condition.
4.Patients deemed inappropriate by the attending physician.

Target sample size

90


Research contact person

Name of lead principal investigator

1st name Yutaka
Middle name
Last name Yamamoto

Organization

Kindai University Nara Hospital

Division name

Department of Urology

Zip code

630-0293

Address

1248-1 Otodacho Ikoma-city, Nara

TEL

074-377-0880

Email

yamamotokindai@yahoo.co.jp


Public contact

Name of contact person

1st name Yutaka
Middle name
Last name Yamamoto

Organization

Kindai University Nara Hospital

Division name

Department of Urology

Zip code

630-0293

Address

1248-1 Otodacho Ikoma-city, Nara

TEL

074-377-0880

Homepage URL


Email

yamamotokindai@yahoo.co.jp


Sponsor or person

Institute

Department of Urology, Kindai University Nara Hospital.

Institute

Department

Personal name



Funding Source

Organization

none

Organization

Division

Category of Funding Organization

Other

Nationality of Funding Organization



Other related organizations

Co-sponsor


Name of secondary funder(s)



IRB Contact (For public release)

Organization

Kindai University Nara Hospital Certified Review Board

Address

1248-1 Otodacho Ikoma-city, Nara

Tel

074-377-0880

Email

n-rinri@med.kindai.ac.jp


Secondary IDs

Secondary IDs

NO

Study ID_1


Org. issuing International ID_1


Study ID_2


Org. issuing International ID_2


IND to MHLW



Institutions

Institutions



Other administrative information

Date of disclosure of the study information

2020 Year 10 Month 27 Day


Related information

URL releasing protocol

https://center6.umin.ac.jp/cgi-open-bin/icdr/ctr_view_cb.cgi?recptno=R000048236&flwp_key=1004IRoXcCd

Publication of results

Unpublished


Result

URL related to results and publications

https://center6.umin.ac.jp/cgi-open-bin/icdr/ctr_view_cb.cgi?recptno=R000048236&flwp_key=1004IRoXcCd

Number of participants that the trial has enrolled

88

Results

A total of 77 patients completed all scheduled assessments. Serum testosterone levels and MMSE scores were almost identical in the 2 cohorts at baseline. With 36-months follow up, significant decrease on the serum testosterone levels were observed in patients on ADT, but not in controls. As measured by MMSE, no statistically significant differences in cognitive function were observed at 6, 12 and 36 months compared to baseline in either cohort.

Results date posted

2022 Year 11 Month 08 Day

Results Delayed


Results Delay Reason


Date of the first journal publication of results


Baseline Characteristics

Prostate cancer group
1.Patients who received androgen deprivation therapy.
2.Eastern Cooperative Oncology Group performance status (ECOG-PS): 0-2.
3.Expected survival is more than 12 months.
4.Patients who understand this research plan and have given their consent.

Control group
1.Patients with suspected prostate cancer who require regular monitoring.
2.Eastern Cooperative Oncology Group performance status (ECOG-PS): 0-2.
3.Expected survival is more than 12 months.
4.Patients who understand this research plan and have given their consent.

Participant flow

1.Assessing changes in cognitive functioning scores from the baseline to 3 years later.
2.Correlation between the levels of serum testosterone and changes in cognitive function scores.
3.Statistical analysis of correlation with clinical information.

Adverse events

none

Outcome measures

1.Assessing changes in cognitive functioning scores from the baseline to 3 years later.
2.Correlation between the levels of serum testosterone and changes in cognitive function scores.
3.Statistical analysis of correlation with clinical information.

Plan to share IPD


IPD sharing Plan description



Progress

Recruitment status

Enrolling by invitation

Date of protocol fixation

2017 Year 08 Month 01 Day

Date of IRB

2017 Year 08 Month 01 Day

Anticipated trial start date

2017 Year 09 Month 01 Day

Last follow-up date

2021 Year 08 Month 01 Day

Date of closure to data entry


Date trial data considered complete


Date analysis concluded



Other

Other related information

1.Assessing changes in cognitive functioning scores from the baseline to 3 years later.
2.Correlation between the levels of serum testosterone and changes in cognitive function scores.
3.Statistical analysis of correlation with clinical information.


Management information

Registered date

2020 Year 10 Month 27 Day

Last modified on

2022 Year 11 Month 08 Day



Link to view the page

Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000048236


Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name